Cholesterol and the truths no one wants to tell you. Here's what researchers say...

Initial note: This article was previously published and updated according to scientific and informative criteria to make the information clearer and verifiable. The text is for informational purposes only and does not replace personalized medical advice.

IN BRIEF

• Systemic inflammation is recognized as an important factor in the progression of cardiovascular diseases, independent of LDL cholesterol levels alone.
• Not all LDL lipoproteins carry the same risk: small, dense particles (sdLDL) and oxidized LDL are associated with greater atherogenicity than larger LDL.
• High triglyceride levels, often associated with diets rich in refined carbohydrates and insulin resistance, promote the production of VLDL particles and the formation of sdLDL.
• Interventions that reduce inflammation (pharmacological or lifestyle) have shown effects on reducing cardiovascular events in selected clinical studies, but translating these into individual recommendations requires caution.

Abstract: what does science say?

The body of evidence suggests that cardiovascular risk does not depend solely on the amount of cholesterol in the blood, but also on its quality, systemic inflammation, and metabolic processes related to carbohydrates and triglycerides. Clinical studies aimed at reducing systemic inflammation have observed reductions in cardiovascular events in selected contexts, while observational research and meta-analyses show associations between elevated triglycerides, small LDL particles, and increased coronary risk. The evidence supports dietary and preventive approaches that reduce glycemic excess and inflammation, while acknowledging the limitations of studies and the need for personalization.

MAIN SECTION

What's important to understand: inflammation, lipids, and risk

Chronic low-grade inflammation is now considered a factor contributing to the progression of atherosclerosis and cardiovascular events. Clinical evidence has shown that targeted reduction of inflammation can decrease the risk of cardiac events in selected populations, even without major changes in LDL-C levels [1][2]. This does not negate the role of cholesterol-rich lipoproteins as a risk factor; rather, it broadens the picture, highlighting that risk and protection depend on multiple interrelated mechanisms (lipids, inflammation, oxidative stress, glycemic metabolism).

The surprising measure: C-reactive protein and predictive role

High-sensitivity C-reactive protein (hs-CRP) is a simple and common marker for assessing systemic inflammation. Randomized studies on drugs that reduced hs-CRP have observed reductions in cardiovascular events in particular patient groups, suggesting that inflammation is a relevant target for prevention beyond lipid control [1][2]. However, hs-CRP is an indicator and not a direct cause: its interpretation requires the full clinical context.

LDL: not all particles are equal

Traditional measures (total cholesterol, LDL-C) provide useful information but do not describe the variability of lipid particles. Small, dense LDL particles (sdLDL) have been associated in prospective studies with a higher risk of coronary ischemia compared to larger LDL [5], and a recent meta-analysis confirms the relationship between sdLDL and coronary artery disease [6]. Therefore, risk assessment may require more advanced measures or the use of clinical surrogates (e.g., elevated triglycerides with low HDL) to estimate the presence of sdLDL.

Carbohydrates, triglycerides, and metabolism: how it all connects

High intakes of refined carbohydrates and sugars can promote hypertriglyceridemia and hyperinsulinemia in predisposed individuals; this metabolic picture promotes the production of triglyceride-rich VLDL and their subsequent transformation into sdLDL, increasing atherogenic risk [4][8]. Meta-analyses of low carb diets show average reductions in triglycerides and increases in HDL compared to low-fat diets, with variable effects on LDL [4].

LDL oxidation and oxidative stress

Oxidative modification of LDL is a biological mechanism that increases its uptake by macrophages and the formation of so-called foam cells in arterial walls. Scientific reviews consolidate the role of LDL oxidation as a relevant process in atherogenesis, although direct clinical application (e.g., routine testing or specific antioxidant therapies) remains complex and unresolved [7].

PRACTICAL SECTION

What it means in practice

For the general public, the evidence indicates that assessing cardiovascular risk requires more than just a single number (total cholesterol). It is useful to consider the complete metabolic profile: triglycerides, HDL, glycemia, blood pressure, inflammatory status (hs-CRP when indicated), and personal clinical factors. Some approaches with evidence of risk reduction include dietary patterns rich in vegetables, unsaturated fats (e.g., olive oil), fish, and dietary fiber, as observed in population studies and prevention trials [3]. At the same time, diets that reduce the intake of refined carbohydrates can lower triglycerides and improve lipoprotein profiles in many people [4]. Cholesterol-lowering drugs remain essential for those with clinical indications; in some cases, reducing inflammation can contribute to the observed benefits [1][2].

KEY POINTS TO REMEMBER

• Systemic inflammation contributes to cardiovascular risk and can be measured with markers such as hs-CRP.
• Small, dense LDL particles are associated with greater atherogenic risk than larger LDL; elevated triglycerides are a useful signal to suspect their presence [5][6].
• Reducing refined carbohydrates tends to lower triglycerides and can promote less atherogenic lipid profiles in many individuals [4].
• 'Mediterranean' dietary interventions have shown reductions in cardiovascular events in primary prevention trials [3].

LIMITATIONS OF EVIDENCE

It is crucial to distinguish between observational association and demonstrated causality: observational studies show correlations between behaviors, biomarkers, and disease, but do not alone prove a causal link. Randomized clinical trials provide the highest level of evidence for causality; for example, studies that aimed to reduce inflammation have shown benefits in selected populations, but the results are not automatically generalizable to all patients [2]. Common methodological limitations include the variability of lipid and inflammatory measures, different follow-up durations, heterogeneity of tested diets, and the presence of confounding factors (age, smoking, comorbidities). Furthermore, much research reports average effects: individual response may depend on genetics, lifestyle, and underlying metabolic conditions. For these reasons, clinical decisions must be based on individual assessment and professional consultation.

Editorial conclusion

The relationship between cholesterol, inflammation, and cardiovascular disease is complex but well-studied. Modern evidence shifts the focus from the sole numerical value of total cholesterol to a multifactorial picture that includes the quality of lipid particles, inflammatory status, and carbohydrate and triglyceride metabolism. This does not contradict the importance of lipid-lowering therapies when indicated, but calls for an integrated view of prevention: measuring and acting on metabolic and inflammatory factors, promoting dietary patterns based on unprocessed foods, and personalizing clinical choices. For each individual, diagnostic and therapeutic choices should be agreed upon with the treating physician.

Editorial note

This article is an updated informative summary and does not replace an individual clinical evaluation. The information is based on peer-reviewed scientific studies with verified DOIs; the selection of sources prioritizes research with direct relevance to the topic. For personalized questions or to manage your cardiovascular risk, consult a healthcare professional.

SCIENTIFIC RESEARCH

1. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‑reactive protein. New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa0807646. [JUPITER trial that showed rosuvastatin reduced events and hs‑CRP].
2. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa1707914. [CANTOS trial demonstrating effects of targeting inflammation on CV events].
3. Estruch R, Ros E, Salas‑Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa1200303. [PREDIMED trial on Mediterranean diet and cardiovascular outcomes].
4. Hu T, Mills KT, Yao L, et al. Effects of low‑carbohydrate diets versus low‑fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. American Journal of Epidemiology. DOI: https://doi.org/10.1093/aje/kws264. [Meta-analysis comparing low-carb and low-fat diets, with effects on triglycerides and HDL].
5. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low‑density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation. DOI: https://doi.org/10.1161/01.CIR.95.1.69. [Prospective study linking sdLDL to ischemic heart disease].
6. Liou L, Kaptoge S, et al. Association of small, dense LDL‑cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: a systematic review and meta-analysis. PLoS ONE. DOI: https://doi.org/10.1371/journal.pone.0241993. [Systematic review/meta-analysis on sdLDL and CHD].
7. Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low‑density lipoproteins in the pathogenesis of atherosclerosis. Annual Review of Medicine. DOI: https://doi.org/10.1146/annurev.me.43.020192.001251. [Review on ox‑LDL and atherogenesis].
8. Ginsberg HN, Elam MB, Lovato LC, et al.; AHA Scientific Statement. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. DOI: https://doi.org/10.1161/CIR.0b013e3182160726. [Statement on role of triglycerides and remnant lipoproteins in CVD].